Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Astria Therapeutics ( (ATXS) ) just unveiled an announcement.
Astria Therapeutics has announced the design of the ALPHA-ORBIT Phase 3 clinical trial for navenibart, a treatment for hereditary angioedema, which will feature both every 3- and 6-month treatment arms. This trial aims to support global registration and is expected to initiate in Q1 2025. The company is pioneering flexible dosing options to potentially make navenibart a market-leading choice for HAE therapy, and the trial design incorporates feedback from regulatory authorities and collaboration with patients and physicians.
More about Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases. Its lead program is navenibart, a monoclonal antibody inhibitor of plasma kallikrein for the treatment of hereditary angioedema (HAE), and it also has a second program, STAR-0310, in development for atopic dermatitis.
YTD Price Performance: -16.95%
Average Trading Volume: 289,393
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $420.4M
For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects